Silence Therapeutics plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Silence Therapeutics plc (SLNCF) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 5.90 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-05
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.90M shares, a 55.15% increase from fiscal 2024.
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.80M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|
| 2025-12-31 | 5.90M shares 10-K · filed 2026-03-05 |
| 2024-12-31 | 3.80M shares 10-K · filed 2025-02-27 |